Claiming that prolonging Charlie's life would cause unnecessary suffering, British judges had ruled that London's Great Ormond Hospital could remove life support without the consent of the parents. The hospital granted Charlie an extension on life support so his parents may have a few more moments with him.

During the extension, a team of seven medical experts told the hospital that unpublished data on an experimental drug suggest a treatment which may improve the condition of Charlie’s brain. One of the experts is a neurologist and a researcher located at the Bambino Gesu Hospital in Rome – a Vatican hospital who's request to transfer Charlie to their facility was also recently denied.

Additionally, a U.S. specialist in mitochondrial diseases speculated in a video last Thursday that the experimental treatment, nucleoside therapy, has a success rate of at least 10 percent and a potential high of 56 percent.

Since experts have submitted new data that advocates for Charlie’s possible recovery, the Great Ormond Hospital has asked the courts to reopen the baby’s case that Charlie be transferred to the U.S. for nucleoside therapy, which his parents have successfully fundraised over $1 million for.

Charlie was diagnosed with Mitochondrial Depletion Syndrome – a fatal disease which progressively weakens the muscles and causes brain damage. The genetic disease is very rare, and Charlie is thought to be only one out of 16 people in the world diagnosed with the disease.

Despite Charlie’s low potential for survival, his parents have received U.S. and Vatican support for their right to fight for his life.

A statement was issued July 2 on behalf of Pope Francis, saying that the pontiff “prays for them, wishing that their desire to accompany and care for their own child to the end will be respected.”